Meta Information
ID:foxo4-dri
Name:FOXO4-DRI
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-07-02T07:03:07Z
Model
phase-b-newfiles-claude-opus-4.8
Interactions
Target id:
/condition/fda-compounding-risk
Target name:
Regulatory / experimental status
Severity:
major
Interaction type:
adverse
Nature:
informational
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
FOXO4-DRI is an experimental senolytic peptide with no human safety data and no approved product.
Actionable advice:
Not approved for human use; no quality assurance or established dosing. Experimental only.
Validation status:
validated_via_regulatory
Evidence tier:
tier_b
Evidence basis:
regulatory_advisory_verbatim
Evidence anchors:
Exact phrase from label:
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Label source:
US FDA compounding advisory. FOXO4-DRI is an unapproved experimental peptide.
Action type:
informational_none
Target id:
/condition/active-cancer
Target name:
Active cancer
Severity:
moderate
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
FOXO4-DRI disrupts the FOXO4-p53 interaction to kill senescent cells; effects on p53 signaling in active cancer are unknown and potentially harmful.
Actionable advice:
It is best avoided in active cancer; interactions with tumor p53 biology are unstudied.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
FOXO4-DRI perturbs p53 localization to trigger senescent-cell apoptosis; unknown/uncertain effects in malignancy. Theoretical.
Label source:
Class inference
Action type:
avoid
Target id:
/class/chemotherapy-radiation
Target name:
Chemotherapy / radiation
Severity:
moderate
Interaction type:
synergistic
Nature:
relative
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Senolytics are being studied to clear therapy-induced senescent cells, but combined effects with chemo/radiation are unproven and could alter efficacy or toxicity.
Actionable advice:
This is best used only in supervised research settings, and self-combining with cancer therapy is best avoided.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Senolytic clearing of therapy-induced senescent cells is investigational; combined efficacy/toxicity with chemo/RT unproven. Theoretical.
Label source:
Class inference
Action type:
monitor